CCI
AVDL

Columbus Circle Investors’s Avadel Pharmaceuticals AVDL Stock Holding History

Columbus Circle Investors’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-23,924
Closed -$251K – 182
2017
Q3 		$251K Sell
23,924
-27,213
-53% -$260K ﹤0.01% 284
2017
Q2 		$564K Buy
51,137
+7,315
+17% +$73.4K 0.01% 233
2017
Q1 		$424K Sell
43,822
-5,493
-11% -$54.9K 0.01% 266
2016
Q4 		$512K Sell
49,315
-256
-0.5% -$2.81K 0.01% 245
2016
Q3 		$615K Sell
49,571
-13,242
-21% -$173K 0.01% 264
2016
Q2 		$675K Buy
62,813
+32,458
+107% +$346K 0.01% 240
2016
Q1 		$335K Sell
30,355
-43,060
-59% -$428K ﹤0.01% 255
2015
Q4 		$896K Sell
73,415
-30,420
-29% -$474K 0.01% 259
2015
Q3 		$1.69M Sell
103,835
-12,574
-11% -$277K 0.01% 234
2015
Q2 		$2.47M Sell
116,409
-11,596
-9% -$208K 0.02% 239
2015
Q1 		$2.3M Buy
128,005
+15,513
+14% +$243K 0.02% 249
2014
Q4 		$1.93M Buy
+112,492
New +$1.61M 0.01% 245
2014
Q1 		– Sell
-58,132
Closed -$468K – 285
2013
Q4 		$468K Sell
58,132
-38,125
-40% -$269K ﹤0.01% 281
2013
Q3 		$631K Buy
96,257
+17,246
+22% +$106K ﹤0.01% 282
2013
Q2 		$485K Buy
+79,011
New +$408K ﹤0.01% 266

Other funds holding AVDL

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Columbus Circle Investors's AVDL Position: Q4 2017 in Review

Columbus Circle Investors sold out of Avadel Pharmaceuticals (AVDL) in Q4 2017, closing a stake of 23,924 shares — an estimated $251K sold.

Columbus Circle Investors first reported a position in AVDL in Q2 2013 and held it in 15 quarters. The position peaked at $2.47M in Q2 2015. 83 funds tracked by Wall St. Rank hold AVDL as of Q4 2017.

  • Columbus Circle Investors reported no remaining Avadel Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Columbus Circle Investors sold 23,924 Avadel Pharmaceuticals shares in Q4 2017, an estimated $251K.
  • Columbus Circle Investors first reported a position in Avadel Pharmaceuticals in Q2 2013 and held it in 15 quarters.
  • Columbus Circle Investors's Avadel Pharmaceuticals position peaked at $2.47M in Q2 2015.
  • 83 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2017.

Based on Columbus Circle Investors's 13F filing for Q4 2017, filed 2 Feb 2018.